Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients.
Saved in:
| Title: | Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients. |
|---|---|
| Authors: | Perrier, Quentin1 (AUTHOR), Lupo, Julien2 (AUTHOR), Epaulard, Olivier3 (AUTHOR) OEpaulard@chu-grenoble.fr |
| Source: | Transplant Infectious Disease. Dec2023, Vol. 25 Issue 6, p1-3. 3p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 13982273 |
|---|---|
| DOI: | 10.1111/tid.14164 |